Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.

Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S.

Am J Psychiatry. 2001 Nov;158(11):1843-9.

PMID:
11691690
2.

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S.

Am J Psychiatry. 2004 May;161(5):826-35.

PMID:
15121647
3.

Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography.

Voineskos AN, Wilson AA, Boovariwala A, Sagrati S, Houle S, Rusjan P, Sokolov S, Spencer EP, Ginovart N, Meyer JH.

Psychopharmacology (Berl). 2007 Sep;193(4):539-45.

PMID:
17497139
4.

Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression.

Kennedy SH, Evans KR, Krüger S, Mayberg HS, Meyer JH, McCann S, Arifuzzman AI, Houle S, Vaccarino FJ.

Am J Psychiatry. 2001 Jun;158(6):899-905.

PMID:
11384897
5.

Association between citalopram serum levels and clinical improvement of patients with major depression.

Ostad Haji E, Tadić A, Wagner S, Dragicevic A, Müller MJ, Boland K, Rao ML, Fric M, Laux G, Hiemke C.

J Clin Psychopharmacol. 2011 Jun;31(3):281-6. doi: 10.1097/JCP.0b013e318218f503.

PMID:
21508853
6.

Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study.

Catafau AM, Perez V, Plaza P, Pascual JC, Bullich S, Suarez M, Penengo MM, Corripio I, Puigdemont D, Danus M, Perich J, Alvarez E.

Psychopharmacology (Berl). 2006 Dec;189(2):145-53.

PMID:
17033844
7.

Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression.

Smith GS, Kahn A, Sacher J, Rusjan P, van Eimeren T, Flint A, Wilson AA.

Am J Geriatr Psychiatry. 2011 Dec;19(12):1016-25. doi: 10.1097/JGP.0b013e318227f83f.

8.

PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram.

Lundberg J, Christophersen JS, Petersen KB, Loft H, Halldin C, Farde L.

Int J Neuropsychopharmacol. 2007 Dec;10(6):777-85.

PMID:
17201996
9.

5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB.

Bhagwagar Z, Murthy N, Selvaraj S, Hinz R, Taylor M, Fancy S, Grasby P, Cowen P.

Am J Psychiatry. 2007 Dec;164(12):1858-65.

PMID:
18056241
10.

Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression.

Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr.

Am J Psychiatry. 2003 Mar;160(3):522-32.

PMID:
12611834
11.

Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes.

Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, Goulding V, Kennedy J, Wilson AA.

Arch Gen Psychiatry. 2004 Dec;61(12):1271-9.

PMID:
15583118
12.

Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652.

Kent JM, Coplan JD, Lombardo I, Hwang DR, Huang Y, Mawlawi O, Van Heertum RL, Slifstein M, Abi-Dargham A, Gorman JM, Laruelle M.

Psychopharmacology (Berl). 2002 Dec;164(4):341-8.

PMID:
12457263
13.

Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.

Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Küfferle B, Barnas C, Stastny J, Praschak-Rieder N, Pezawas L, de Zwaan M, Quiner S, Pirker W, Asenbaum S, Podreka I, Brücke T.

World J Biol Psychiatry. 2002 Jul;3(3):133-46. Review.

PMID:
12478878
14.

The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study.

Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH.

Am J Psychiatry. 2001 Jan;158(1):78-85.

PMID:
11136637
15.

Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram.

Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, Lanzenberger R, Spindelegger C, Asenbaum S, Holik A, Dudczak R.

Int Clin Psychopharmacol. 2009 May;24(3):119-25. doi: 10.1097/YIC.0b013e32832a8ec8. Review.

PMID:
19367152
16.

A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?

Sanchez C, Reines EH, Montgomery SA.

Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. Review.

17.

Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings.

Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang SC, Wu HM, Ho ML, Ho MK, Au SC, Maidment K, Baxter LR Jr.

Arch Gen Psychiatry. 2001 Jul;58(7):631-40.

PMID:
11448368
18.

High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.

Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y.

Arch Gen Psychiatry. 2003 Apr;60(4):386-91.

PMID:
12695316
19.
20.

Citalopram treatment of paroxetine-intolerant depressed patients.

Thase ME, Ferguson JM, Lydiard RB, Wilcox CS.

Depress Anxiety. 2002;16(3):128-33.

PMID:
12415538

Supplemental Content

Support Center